Assessing responsiveness over time of the PROMIS (R) pediatric symptom and function measures in cancer, nephrotic syndrome, and sickle cell disease

Bryce B. Reeve, University of North Carolina
Lloyd J. Edwards, University of North Carolina
Byron C. Jaeger, University of North Carolina
Pamela S. Hinds, Children's National Health System
Carlton Dampier, Emory University
Debbie S. Gipson, University of Michigan
David T. Selewski, University of Michigan
Jonathan P. Troost, University of Michigan
David Thissen, University of North Carolina
Vaughn Barry, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Quality of Life Research
Volume: Volume 27, Number 1
Publisher: Springer Verlag (Germany) | 2018-01-01, Pages 249-257
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1007/s11136-017-1697-z
Permanent URL: https://pid.emory.edu/ark:/25593/tmq2h

Final published version: http://dx.doi.org/10.1007/s11136-017-1697-z

Copyright information:
© 2017, Springer International Publishing AG.

Accessed September 7, 2019 2:30 AM EDT
Assessing Responsiveness over Time of the PROMIS® Pediatric Symptom and Function Measures in Cancer, Nephrotic Syndrome, and Sickle Cell Disease

Bryce B. Reeve, PhD1,2, Lloyd J. Edwards, PhD3, Byron C. Jaeger, PhD3, Pamela S. Hinds, PhD, RN, FAAN4,5, Carlton Dampier, MD6,7, Debbie S. Gipson, MD8, David T. Selewski, MD, MS8, Jonathan P. Troost, PhD8, David Thissen, PhD9, Vaughn Barry, PhD, MPH6,7, Heather E. Gross, MEd1, and Darren A. DeWalt, MD, MPH10

1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
2Department of Health Policy and Management, University of North Carolina, Chapel Hill, NC, USA
3Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA
4Department of Nursing Research and Quality Outcomes, Children’s National Health System, Washington, DC, USA
5Department of Pediatrics, George Washington University, Washington, DC, USA
6Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
7AFLAC Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Atlanta GA
8C.S. Mott Children’s Hospital, University of Michigan, Ann Arbor, MI, USA
9Department of Psychology and Neuroscience, University of North Carolina, Chapel Hill, NC, USA
10Division of General Medicine and Clinical Epidemiology, UNC School of Medicine, Chapel Hill, NC, USA

Abstract

Purpose—Previous studies provided evidence for the validity of the PROMIS Pediatric measures in cross-sectional studies. This study evaluated the ability of the PROMIS Pediatric measures to

Contact Information: Bryce B. Reeve, PhD, Professor, Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, 1101-D McGavran-Greenberg Hall, CBI#7411, 135 Dauer Dr, Chapel Hill, NC 27599-7411, Phone: 919-962-5434, bbreeve@email.unc.edu.

Compliance with Ethical Standards:
Conflict of Interest: Dr. DeWalt was an author of some of the items in the PROMIS measures and owns the copyright for these items. Dr. DeWalt has given an unlimited free license for the use of the materials to the PROMIS Health Organization. Both Dr. DeWalt and Dr. Reeve are former members of the PROMIS Health Organization Board of Directors. There are no other conflicts of interest to report for other authors.
Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent: Informed consent was obtained from all individual participants included in the study.
detect change over time in children and adolescents with cancer, nephrotic syndrome (NS), or sickle cell disease (SCD).

**Methods**—Participants (8–17 years) completed measures of Fatigue, Pain Interference, Anger, Anxiety, Depressive Symptoms, Mobility, Upper Extremity and Peer Relationships at 3 or 4 time points (T1-T4). Between T1 and T2, children with cancer received chemotherapy and children with SCD experienced a pain exacerbation. Children with NS were first assessed during active disease (T2), with T3 and T4 conducted at disease remission. For the primary analysis of responsiveness, we expected better scores at T3 (recovery) compared to T2 (event) for all diseases. T1 and T4 are also expected to have better scores than T2. Linear mixed models were used and adjusted for time, gender, age, race/ethnicity, education, comorbid conditions, and disease.

**Results**—Enrolled were 96 children with cancer, 121 children with SCD, and 127 children with NS. Fatigue, Pain Interference, Mobility, and Upper Extremity scores worsened from T1 (baseline) to T2 (event) ($p < 0.01$), and significantly improved from T2 to T3 and T4 ($p < 0.01$). Similarly, Anxiety and Depressive Symptoms significantly improved from T2 to T3 and T4 ($p < 0.01$).

**Conclusions**—This study provides evidence for the responsiveness of 7 PROMIS Pediatric measures to clinical disease state in 3 chronic illnesses. The findings support use of PROMIS Pediatric measures in clinical research.

**Keywords**

Patient-reported outcomes; responsiveness; pediatrics; cancer; nephrotic syndrome; sickle cell disease

---

**INTRODUCTION**

The National Institutes of Health (NIH) initiated the Patient-Reported Outcomes Measurement Information System® (PROMIS®) project in 2004 with the goal to provide researchers and clinicians access to standardized, psychometrically-robust, patient-reported measures (pediatric and adult) of key symptom and function domains. A central principal is that these measures could be useful across a broad range of conditions and diseases to capture the impact of the disease and treatment on the lives of the patients. The non-disease specific measures of the PROMIS measurement system allow the comparison of scores from one group of individuals to another to evaluate relative disease burden. Given the broad scope of the PROMIS measures, it is critical to evaluate the psychometric properties in multiple disease populations to provide evidence that the measures are valid and reliable assessments of the symptom and function domains they measure.

The PROMIS Pediatric measures are designed for children and adolescents between 8 and 17 years of age. Extensive qualitative and quantitative methods have been used to design and evaluate, in multiple diverse patient groups, the PROMIS measures of: Physical Function – Mobility [1], Physical Function – Upper Extremity [1], Pain Interference [2], Fatigue [3], Depressive Symptoms [4], Anxiety [4], Anger [5], and Peer Relationships [6]. In addition, a multi-site study collected data from 1447 children and adolescents with chronic health conditions, including sickle cell disease, kidney disease, cancer, rehabilitative needs, obesity,
and rheumatic disease, in order to validate the PROMIS Pediatric measures in cross-sectional studies [7–11].

It is also critical to evaluate the responsiveness of the PROMIS Pediatric measures over time and changing clinical situations. Responsiveness is an aspect of validity that indicates the ability of a PRO measure to detect change over time when it is expected. For PROMIS Pediatric measures to be adopted for use in clinical trials, there must be evidence of their responsiveness to inform the efficacy evaluation of the intervention or the disease treatment impact under study. The goal of this study was to evaluate the responsiveness of 8 PROMIS Pediatric measures in diverse samples of children and adolescents with cancer, sickle cell disease (SCD), or nephrotic syndrome (NS).

**METHODS**

**Participants and Study Design**

The University of North Carolina (UNC) served as the central coordinating center to support the following sites focused on specific diseases: Children’s National Health System – Cancer; University of Michigan – Nephrotic Syndrome, and Emory University – Sickle Cell Disease. The study reported here represents a secondary analysis of three separate studies of responsiveness of the PROMIS Pediatric measures at their respective sites. Each site had the freedom to select the number of assessment points, timing of the assessment points, sample size, and PROMIS domains; thus, there is heterogeneity across the three diseases because of the differential experience of symptom burden and functional status by disease. However, each had a common goal to assess responsiveness over time of the PROMIS Pediatric measures for children experiencing changing health status.

Common eligibility criteria across all diseases included children and adolescents between the ages of 8 and 17 years of age, ability to read and speak English (because at the time of the study there were no translations of the PROMIS Pediatric measures), functional computer skills (defined as the ability to see and interact with a computer screen, keyboard, and mouse), and willingness to give written assent/permission for study participation. Excluded were children and adolescents who had any concurrent medical or psychiatric condition that precluded study participation, or cognitive or other (e.g., visual) impairments that interfered with completing a self-administered, computer-based questionnaire. Additional eligibility criteria specific to a disease are provided below. All sites received approval from their respective Institutional Review Boards.

**Cancer**

Eligible children and adolescents were diagnosed with a childhood cancer, scheduled to receive a course of anti-neoplastic (not biologic agent only) chemotherapy from course 2 forward, and not currently enrolled on a Phase 1 clinical trial. The study included 3 time points. Time 1 (T1) occurred 1 to 2 days before an early course of chemotherapy. Time 2 (T2) occurred 7 to 16 days following chemotherapy initiation at the time when the patient’s nadir was projected. T3 occurred within 1 to 2 days preceding the next course of scheduled...
chemotherapy or approximately two weeks following T2. More study details are provided elsewhere [12].

Based on clinical experience, we hypothesized that PROMIS physical symptoms and function scores at T1 would be within the normal range; however, children would have elevated emotional distress (depression and anxiety) given the proximity of the assessment relative to the cancer diagnosis and start-up of chemotherapy. Following chemotherapy and at the projected time of the nadir (T2), we hypothesized physical symptom and function scores would be worse compared to T1 (except depression and anxiety), and that the symptom and function scores would be improved at T3 compared to T2. The child’s relationship with peers was not expected to change due to the relatively short treatment cycles.

**Nephrotic Syndrome**

Eligible children and adolescents included those with active nephrotic syndrome defined as the presence of nephrotic range proteinuria (≥2+ urinalysis and edema or urine protein/creatinine ratio >2g/g) at the time of the first PROMIS assessment. Participants were recruited from 14 academic medical centers across the US and Canada.

Children completed questionnaires at 3 time points. For purposes of this study’s analyses, there was no T1 (baseline) comparable measure similar to the children with cancer or sickle cell disease. Children with NS were first assessed during active disease (T2), with T3 conducted when they reached complete remission or at three months after T2 if remission did not occur and a subsequent follow-up (T4) at 12 months after T2. More study details are provided elsewhere [13].

We hypothesized that T2 would be the worst symptom and poorest functional status for the children experiencing NS activity. We hypothesized that symptom levels and functioning would be better at T3 and T4 follow-up periods when the children were in remission. Peer Relationships scores were not expected to change because of change in health status.

**Sickle Cell Disease**

A convenience sample of SCD patients was recruited during routine clinic visits at 3 clinical sites that were part of the same large SCD program (Children’s Healthcare of Atlanta). Eligibility criteria included one or more acute care visits for pain in the previous year. More details on the study are provided elsewhere [14,15].

Children completed questionnaires at up to 4 time points. T1 provided a baseline assessment of the child’s health status. T2 assessment occurred at the end of a subsequent hospitalization for a pain exacerbation, 16.6 ± 19.1 months from baseline visit. T3 pain recovery assessment occurred at a median interval of 20 days (range 7–67 days) from their hospitalization assessment. T4 occurred at a subsequent routine clinic visit 1.5 ± 0.56 years following T1. Not all children enrolled in the study provided T2 and T3 data as only 45% of the children experienced a pain exacerbation that led to a hospitalization. Thus, sample sizes for T2 and T3 will be lower than T1 and T4 as not all children experienced a pain exacerbation.
We hypothesized that children with SCD at T2 to have the worst symptom levels and poorest functioning due to the pain exacerbation compared with T1, T3, and T4. The greatest change would occur between T2 and T3 (recovery phase) with Pain Interference showing the biggest change relative to other symptoms. Because of the short duration of the pain episode, Peer Relationships status were not expected to change.

**Measures**

The vast majority of participating children completed computerized-adaptive testing (CAT) versions of the PROMIS Pediatric measures of Pain Interference, Mobility, Upper Extremity, Fatigue, Depressive Symptoms, Anxiety, Anger, and Peer Relationships. The CAT and other data were collected using the Assessment Center platform (https://www.assessmentcenter.net). CAT tailors the questionnaire for the participant by selecting appropriately informative questions based on the individual’s responses to previously completed questions[16]. The result is a reliable assessment with minimal response burden. If the participants did not have access to the web, then the PROMIS Pediatric 8-item short form for each health domain was used. PROMIS pediatric measures are scored on a T-score metric with mean of 50 and standard deviation of 10 in the original PROMIS pediatric item bank calibration [17]. Higher scores for symptom measures (i.e., Fatigue, Pain Interference, Depressive Symptoms, Anxiety, Anger) indicate worse symptom experiences, whereas higher scores for function measures (i.e., Mobility, Upper Extremity) and Peer Relationships indicate better functioning or relationships, respectively. In a previous study involving children diagnosed with one of five chronic diseases including cancer, SCD, and NS, a 3-point change was determined to be a minimally important difference (MID) [18]. The MID is defined as “the smallest difference in scores of a PRO measure that is perceived by patients as beneficial or harmful, and which would lead the clinician to consider a change in treatment” [19]. The MID was used to identify meaningful change (responsiveness) scores, as determined by patients, parents, and clinicians, beyond findings from a statistical analysis.

Self-reported demographic data were also collected for each sample. For the analyses reported here, only the demographic data captured in common across the 3 sites were included. These variables include: gender (female or male), race (white vs non-white), ethnicity (Hispanic or not), age (continuous), number of comorbid conditions (none vs one or more conditions), and maternal education (high school or less vs some college or more). The presence of other health conditions and highest level of maternal education were reported by the parent/guardian of the participating patient and captured on study case report forms.

**Analyses**

Descriptive statistics were computed for all study variables by disease and by time. The time duration for measurement occasions varied among the three disease types. However, the study design for each disease type consisted of assessment points based on disease events that aligned as indicators of study events, but the time intervals between these assessment points were different based on disease course. Linear mixed models were fit using the lme4 R package [20] for the analysis of longitudinal measures. Each PROMIS outcome (e.g., fatigue, mobility) was modeled independently. Models were adjusted for time, gender, age,
race/ethnicity, maternal education, comorbid conditions, and disease type. Additionally, subject-specific random intercepts controlled for heterogeneity between participants. Goodness of fit criteria were used to facilitate model selection, and included AIC [21], BIC [22], and $R^2$ [23]. $R^2$ was calculated using the r2lmm R package [24]. Of three possible structures for the time variable (categorical, continuous, or both), semi-partial $R^2$ statistics [23] indicated that the categorical formulation explained more variability than each of the other approaches. Missing data were assumed missing completely at random (MCAR) based on sensitivity analyses and previous work [15].

With the alignment of events (time points) standardized across the 3 diseases, T2 is anticipated to be the point of worst symptom experience and functional impact. For primary analyses of responsiveness, lower symptom scores and higher functional scores are anticipated at T3 (recovery phase) compared with T2 (event). For secondary analyses, we compare T1 (baseline) and T4 (follow-up) with T2 (event).

RESULTS

The study included 96 children with cancer, 121 children with SCD, and 127 children with NS. Gender was approximately equally distributed in the cancer and SCD groups, but males comprised 65% of the NS group. The child’s mean age was similar across all 3 disease groups but race differed across the groups. All SCD children were black or African American (except one was mixed race), children with nephrotic syndrome were 28% black, 13% Asian, 8% Hispanic, and 8% other race, and children with cancer were 24% black, 20% Hispanic, and 13% other race. Maternal education was lowest in the SCD group compared to the other two groups. (Table 1).

Evaluation of Responsiveness of the PROMIS Pediatric Measures

Figures 1–3 show the average PROMIS Pediatric scores at T1-T4 for the SCD, cancer, and NS studies. In Figure 1, peak average symptom scores are at T2, the event, as expected for the Pain Interference and Fatigue measures. In Figure 2, average emotional distress scores (Anxiety, Depressive Symptoms, and Anger) are higher at T2 than at T3 or T4, and higher at T2 than T1 for the SCD study. For the cancer study, emotional distress is at the highest level at T1. Figure 3 shows the pattern of the functioning scores across T1-T4 for the three studies; for the Physical Functioning and Peer Relationships scores, the trends are more subtle, but there is a tendency for the lowest average functioning scores and relationship score to be at T2, as expected for the function domains.

Table 2 provides the mixed model results for each of the PROMIS Pediatric symptom domains of Fatigue, Pain Interference, Anger, Anxiety, and Depressive Symptoms. The reference time point was set at T2 for all diseases as this was the point when the child or adolescent was expected to have the worst health status relative to other time points due to chemotherapy (cancer), active disease (nephrotic syndrome), or pain exacerbation (sickle cell disease). Thus, negative regression weights ($b$) for T1, T3, and T4 in Table 2 indicate symptoms were less severe than T2. From T1 (baseline) to T2 (event), Fatigue ($b = -3.1, p < 0.01$) and Pain Interference ($b = -2.6, p < 0.01$) scores significantly worsened. From T2 (event) to T3 (recovery), all symptoms improved: Fatigue ($b = -6.4, p < 0.001$), Pain...
Interference ($b = -5.5$, $p < 0.001$), Anger ($b = -3.3$, $p < 0.001$); Anxiety ($b = -4.3$, $p < 0.001$); Depressive Symptoms ($b = -3.7$, $p < 0.001$). All symptom mean change scores from T2 to T3 exceeded the MID of 3 points. From T2 (event) to T4 (follow-up), all symptoms except Anger improved ($p < 0.01$).

Table 3 provides the mixed model results for both of the PROMIS Pediatric function domains of Physical Function – Mobility, Physical Function – Upper Extremity, and Peer Relationships. From T1 (baseline) to T2 (event), both function domains and relationships decreased on average (represented by positive regression weights in PROMIS T-score units) ($p < 0.05$). From T2 (event) to T3 (recovery), the function scores improved: Mobility ($b = 3.7$, $p < 0.001$), Upper Extremity ($b = 3.1$, $p < 0.01$), Peer Relationships ($b = 1.6$, $p < 0.05$). From T2 to T4 (follow-up), the function scores improved ($p < 0.05$). The physical function domains exceeded the MID of 3 points going from T2 to T3 and from T2 to T4.

**DISCUSSION**

This multi-site, multi-disease longitudinal study provided evidence for the responsiveness of the PROMIS Pediatric measures of Fatigue, Pain Interference, Anxiety, Anger, Depressive Symptoms, Mobility, and Upper Extremity. Using mixed modeling methods, we were able to combine data from children and adolescents with cancer, nephrotic syndrome, and sickle cell disease and examine how PROMIS scores in a more stable health state compared with scores when the child was experiencing a deteriorating health event, including chemotherapy (cancer), disease activity (nephrotic syndrome), and pain exacerbation (sickle cell disease). The magnitude of change from the event to the recovering phase exceeded the minimally important difference of 3 points [18] for all domains expected to change. These findings are consistent with our hypotheses about expected changes in symptoms and function in the 3 groups. Contrary to hypotheses, Peer Relationships did significantly get worse from T1 to T2 and got better from T2 to T1, but the magnitude of change was below the MID and was the least affected compared to the other domains. It could be the collective decline of physical functioning and increased symptom burden experienced by children at T2 slightly decreased children’s reported peer relationships.

The findings from this study add to the validity evidence from other studies that have examined the responsiveness of the PROMIS Pediatric measures. In an online cohort of 276 children with Crohn’s disease (ages 9–17 years), children completed self-report measures at baseline and 6 months later including a measure of Crohn’s disease activity and PROMIS measures of Pain Interference, Fatigue, Anxiety, Depressive Symptoms, and Peer Relationships [25]. Children with improved Crohn’s disease activity from baseline to follow up reported improved scores (larger than the established MID) on all PROMIS Pediatric measures, and children with worse Crohn’s disease activity from baseline to follow-up reported worse scores (larger than the MID) for all domains except Anxiety. In another study, 229 children (ages 8–17 years) from public insurance programs with asthma completed PROMIS Pediatric measures of Pain Interference, Fatigue, Depressive Symptoms, Mobility, and Peer Relationships and measures of asthma control across four time points over 2 years [26]. The study found that children with worsened asthma control
and poorer overall health tended to report deteriorated function and more symptom burden on the PROMIS Pediatric measures, with fatigue showing the greatest change.

The ability of the PROMIS Pediatric Fatigue measure to capture the largest changes compared to the other symptom measures is especially meaningful in children. Fatigue has been reported as the most troubling symptom during and following the recovery period by children experiencing a number chronic conditions including cancer, anemia, and surviving organ transplants. This means that the ability of the PROMIS Pediatric Fatigue measure to capture change is highly relevant to a number of illness groups.

This study had limitations, including limited locality as the cancer data were collected only from a single site and the SCD data were collected from 3 sites in the Atlanta area. Limited locality may raise concerns about the generalizability of findings. However, we do not have reason to believe that children in these localities with these conditions, would vary from others in their response to these questionnaire items. The study was conducted in English language only. Lastly, the assessments did not include the collection of specific occurrence of other life events or stressors which could have had an impact on the PROMIS results beyond the influence of the disease under study.

Conclusions

The PROMIS Pediatric measures, as completed by 8 to 17 year olds experiencing one or more chronic conditions, are able to measure symptom and functional impact for the affected children and adolescents at specified time points and capture clinically meaningful change in health conditions as hypothesized. This means that these measures are able to quantify the impact of disease and treatment on a child or adolescent and further that these measures are now ready to be embedded into clinical trials for treatment of these diverse chronic illnesses.

The responsiveness of the PROMIS Pediatric measures has been documented here for 3 different pediatric chronic conditions and in the literature for 2 additional pediatric chronic conditions that vary in their clinical presentation and in their likely causative factors [25,26]. In addition, there are ongoing efforts to further evaluate the responsiveness of the PROMIS Pediatric measures in additional disease populations. The NIH-funded initiative, Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium [http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-15-014.html] will examine how changes in PROMIS scores are associated with changes in disease status in populations of children with inflammatory bowel disease, cancer, juvenile idiopathic disease, systemic lupus erythematosus, and asthma. These studies will include the PROMIS measures used in this study as well as newer PROMIS Pediatric measures.

Acknowledgments

Funding: This study was funded by the National Institutes of Health (NIH) Common Fund Initiative (grant #: U01AR052181; U2CCA186878).

PROMIS® was funded with cooperative agreements from the National Institutes of Health (NIH) Common Fund Initiative (Northwestern University, PI: David Cella, PhD, U54AR057951, U01AR052177; Northwestern University, PI: Richard C. Gershon, PhD, U54AR057943; American Institutes for Research, PI: Susan (San) D.
Keller, PhD, U54AR057926; State University of New York, Stony Brook, PIs: Joan E. Broderick, PhD and Arthur A. Stone, PhD, U01AR057948, U01AR052170; University of Washington, Seattle, PIs: Heidi M. Crane, MD, MPH, Paul K. Crane, MD, MPH, and Donald L. Patrick, PhD, U01AR057954; University of Washington, Seattle, PI: Dagmar Amtmann, PhD, U01AR052171; University of North Carolina, Chapel Hill, PI: Harry A. Guess, MD, PhD (deceased), Darren A. DeWalt, MD, MPH, Bryce B. Reeve, PhD U01AR052181; Children’s Hospital of Philadelphia, PI: Christopher B. Forrest, MD, PhD, U01AR057956; Stanford University, PI: James F. Fries, MD, U01AR052128; Boston University, PI: Alan Jette, PT, PhD, Stephen M. Haley, PhD (deceased), and David Scott Tuls, PhD (University of Michigan, Ann Arbor), U01AR057929; University of California, Los Angeles, PIs: Dinesh Khanna, MD (University of Michigan, Ann Arbor) and Brennan Spiegel, MD, MSHS, U01AR057936; University of Pittsburgh, PI: Paul A. Pilkinson, PhD, U01AR052155; Georgetown University, PIs: Carol. M. Moinpour, PhD (Fred Hutchinson Cancer Research Center, Seattle) and Arnold L. Potosky, PhD, U01AR057971; Children’s Hospital Medical Center, Cincinnati, PI: Esi M. Morgan Dewitt, MD, MSCE, U01AR052181; University of Maryland, Baltimore, PI: Lisa M. Shulman, MD, U01AR057967; and Duke University, PI: Kevin P. Weintraub, PhD, U01AR052186. NIH Science Officers on this project have included Deborah Ader, PhD, Vanessa Ameen, MD (deceased), Susan Czajkowski, PhD, Basil Eldadah, MD, PhD, Lawrence Fine, MD, DrPH, Lawrence Fox, MD, PhD, Lynne Haverkos, MD, MPH, Thomas Hilton, PhD, Laura Lee Johnson, PhD, Michael Kozak, PhD, Peter Lyster, PhD, Donald Mattison, MD, Claudia Moy, PhD, Louis Quatrano, PhD, Bryce Reeve, PhD, William Riley, PhD, Peter Scheidt, MD, Ashley Wilder Smith, PhD, MPH, Susana Serrate-Sztein, MD, William Phillip Tonkins, DrPH, Ellen Werner, PhD, Tisha Wiley, PhD, and James Witter, MD, PhD. The contents of this article uses data developed under PROMIS. These contents do not necessarily represent an endorsement by the US Federal Government or PROMIS. See www.HealthMeasures.net for additional information on the PROMIS® initiative.

References


24. Jaeger, B. R package version 0.1.0. ed. 2016. r2glmm: Computes R squared for mixed (multilevel) models (LMMs and GLMMs).


Fig 1.
Upper panel: Average PROMIS Pediatric Pain Interference scores at T1-T4 for the Sickle Cell Disease, Cancer, and Nephrotic Syndrome studies. The vertical bars around each average are twice the standard error of the means, for approximately 95% confidence intervals. Lower panel: as above, for PROMIS Pediatric Fatigue scores.
Fig 2.
Upper panel: Average PROMIS Pediatric Anxiety scores at T1-T4 for the Sickle Cell Disease, Cancer, and Nephrotic Syndrome studies. The vertical bars around each average are twice the standard error of the means, for approximately 95% confidence intervals. Center panel: as above, for PROMIS Pediatric Depressive Symptoms scores. Lower panel: as above, for PROMIS Pediatric Anger scores.
Fig 3.
Upper panel: Average PROMIS Pediatric Physical Functioning: Mobility scores at T1-T4 for the Sickle Cell Disease, Cancer, and Nephrotic Syndrome studies. The vertical bars around each average are twice the standard error of the means, for approximately 95% confidence intervals. Center panel: as above, for PROMIS Pediatric Physical Functioning: Upper Extremity/Dexterity scores. Lower panel: as above, for PROMIS Pediatric Peer Relationships scores.
Table 1
Characteristics of Children and Adolescents with Cancer, Nephrotic Syndrome, or Sickle Cell Disease

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Cancer (N = 96)</th>
<th>Nephrotic Syndrome (N = 127)</th>
<th>Sickle Cell Disease (N = 121)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>44 (46%)</td>
<td>44 (35%)</td>
<td>68 (56%)</td>
</tr>
<tr>
<td>Male</td>
<td>52 (54%)</td>
<td>83 (65%)</td>
<td>53 (44%)</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mean (SD)</td>
<td>13.09 (2.96)</td>
<td>12.31 (2.77)</td>
<td>12.50 (3.05)</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-white</td>
<td>48 (50%)</td>
<td>61 (48%)</td>
<td>121 (100%)</td>
</tr>
<tr>
<td>White</td>
<td>48 (50%)</td>
<td>66 (52%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Hispanic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>19 (20%)</td>
<td>10 (8%)</td>
<td>3 (3%)</td>
</tr>
<tr>
<td><strong>Comorbid Conditions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>70 (73%)</td>
<td>86 (68%)</td>
<td>53 (44%)</td>
</tr>
<tr>
<td>1+</td>
<td>22 (23%)</td>
<td>41 (32%)</td>
<td>36 (30%)</td>
</tr>
<tr>
<td><strong>Maternal Education</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High school or less</td>
<td>33 (34%)</td>
<td>73 (58%)</td>
<td>53 (44%)</td>
</tr>
<tr>
<td>Some college or greater</td>
<td>63 (66%)</td>
<td>54 (43%)</td>
<td>68 (56%)</td>
</tr>
<tr>
<td><strong>Completion rates</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1 (baseline)</td>
<td>96 (100%)</td>
<td>---</td>
<td>121 (100%)</td>
</tr>
<tr>
<td>T2 (event)</td>
<td>84 (88%)</td>
<td>127 (100%)</td>
<td>55 (45%)</td>
</tr>
<tr>
<td>T3 (recovery)</td>
<td>86 (90%)</td>
<td>112 (88%)</td>
<td>38 (31%)</td>
</tr>
<tr>
<td>T4 (follow-up)</td>
<td>---</td>
<td>90 (71%)</td>
<td>80 (66%)</td>
</tr>
</tbody>
</table>

Note:
* For each disease, a separate study design was used to assess responsiveness of the PROMIS Pediatric measures. Nephrotic syndrome did not have a T1 assessment when the child was in remission before active disease state (at study enrollment). Cancer did not have a final T4 assessment point after the recovery period. Sickle Cell disease enrolled children when their symptoms were well controlled and followed them for a possible pain exacerbation (requiring hospitalization) over the course of 18 months; thus, only a subset of children with sickle cell disease provided T2 and T3 data.
### Table 2

Mixed model results for PROMIS Pediatric symptoms

<table>
<thead>
<tr>
<th></th>
<th>Fatigue</th>
<th>Pain Interference</th>
<th>Anger</th>
<th>Anxiety</th>
<th>Depressive Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept (adjusted)</td>
<td>51.9 (47.8, 55.9)</td>
<td>49.3 (45.9, 52.8)</td>
<td>46.4 (41.3, 51.5)</td>
<td>47.7 (44.0, 51.3)</td>
<td>50.3 (47.1, 53.6)</td>
</tr>
<tr>
<td>T1 (baseline)</td>
<td>-3.1 ** (-3.3, -0.9)</td>
<td>-2.6 ** (-4.4, -0.7)</td>
<td>1.0 (-1.1, 3.0)</td>
<td>0.2 (-1.5, 1.9)</td>
<td>0.9 (-0.7, 2.4)</td>
</tr>
<tr>
<td>T3 (recovery)</td>
<td>-6.4 *** (-8.3, -4.5)</td>
<td>-5.5 *** (-7.1, -3.9)</td>
<td>-3.3 *** (-5.5, -1.1)</td>
<td>-4.3 *** (-5.7, -2.9)</td>
<td>-3.7 *** (-5.05, -2.43)</td>
</tr>
<tr>
<td>T4 (follow-up)</td>
<td>-6.1 *** (-8.3, -3.9)</td>
<td>-4.0 *** (-5.8, -2.1)</td>
<td>-2.0 (-4.9, 1.0)</td>
<td>-3.3 *** (-4.9, -1.6)</td>
<td>-2.9 *** (-4.46, -1.37)</td>
</tr>
<tr>
<td>Female</td>
<td>3.4 ** (0.9, 6.0)</td>
<td>1.9 (-0.2, 4.0)</td>
<td>2.0 (-1.3, 5.4)</td>
<td>1.6 (-0.7, 3.9)</td>
<td>0.4 (-1.58, 2.47)</td>
</tr>
<tr>
<td>Age</td>
<td>0.3 (-0.2, 0.7)</td>
<td>0.1 (-0.2, 0.5)</td>
<td>-0.3 (-0.8, 0.3)</td>
<td>-0.3 (-0.7, 0.1)</td>
<td>-0.1 (-0.45, 0.24)</td>
</tr>
<tr>
<td>1+ conditions</td>
<td>-1.2 (-3.9, 1.4)</td>
<td>1.1 (-1.1, 3.4)</td>
<td>-1.7 (-5.3, 1.9)</td>
<td>-1.5 (-4.0, 0.9)</td>
<td>-0.4 (-2.58, 1.75)</td>
</tr>
<tr>
<td>Not White</td>
<td>-1.7 (-4.7, 1.2)</td>
<td>-0.2 (-2.7, 2.3)</td>
<td>-3.0 (-7.7, 1.8)</td>
<td>-2.5 (-5.2, 0.3)</td>
<td>-2.7 (-5.11, -0.35)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>3.4 (-0.9, 7.7)</td>
<td>1.2 (-2.5, 4.8)</td>
<td>3.9 (-1.8, 9.6)</td>
<td>3.4 (-0.6, 7.4)</td>
<td>1.3 (-2.17, 4.83)</td>
</tr>
<tr>
<td>H.S. or less</td>
<td>1.9 (-0.8, 4.6)</td>
<td>2.5 * (0.2, 4.8)</td>
<td>1.7 (-2.2, 5.5)</td>
<td>1.8 (-0.7, 4.2)</td>
<td>1.8 (-0.40, 3.95)</td>
</tr>
<tr>
<td>Incident NS</td>
<td>-3.3 * (-6.5, -0.1)</td>
<td>-1.6 (-4.3, 1.1)</td>
<td>2.1 (-0.8, 5.0)</td>
<td>0.2 (-2.3, 2.8)</td>
<td></td>
</tr>
<tr>
<td>Sickle Cell</td>
<td>2.2 (-1.5, 5.9)</td>
<td>5.7 *** (2.6, 8.9)</td>
<td>-0.7 (-5.1, 3.7)</td>
<td>0.2 (-3.2, 3.6)</td>
<td>-1.5 (-4.5, 1.5)</td>
</tr>
<tr>
<td>Model R²</td>
<td>0.16</td>
<td>0.17</td>
<td>0.10</td>
<td>0.14</td>
<td>0.14</td>
</tr>
<tr>
<td>Observations</td>
<td>744</td>
<td>743</td>
<td>442</td>
<td>740</td>
<td>744</td>
</tr>
<tr>
<td>Log Likelihood</td>
<td>-2,889.4</td>
<td>-2,756.7</td>
<td>-1,658.9</td>
<td>-2,715.5</td>
<td>-2,663.1</td>
</tr>
<tr>
<td>AIC</td>
<td>5,806.8</td>
<td>5,541.4</td>
<td>3,343.9</td>
<td>5,459.1</td>
<td>5,354.1</td>
</tr>
<tr>
<td>BIC</td>
<td>5,871.4</td>
<td>5,605.9</td>
<td>3,397.0</td>
<td>5,523.5</td>
<td>5,418.7</td>
</tr>
</tbody>
</table>

Note:

* p<0.05;
** p<0.01;
*** p<0.001;

AIC = Akaike information criteria; BIC = Bayesian Information Criterria.

The intercept can be interpreted as the mean symptom score at T2 (event) for the reference group who are non-Hispanic white, 8-year old boys with cancer, no other health condition and a mother with education more than high school.
### Table 3
Mixed model results for PROMIS Pediatric function domains

<table>
<thead>
<tr>
<th></th>
<th>Mobility</th>
<th>Upper Extremity</th>
<th>Peer Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept (adjusted)</td>
<td>40.4 (37.5, 43.3)</td>
<td>42.5 (39.0, 45.9)</td>
<td>47.7 (44.5, 51.0)</td>
</tr>
<tr>
<td>T1 (baseline)</td>
<td>2.8 *** (1.3, 4.4)</td>
<td>3.0 *** (1.3, 4.8)</td>
<td>1.8 * (0.2, 3.5)</td>
</tr>
<tr>
<td>T3 (recovery)</td>
<td>3.7 *** (2.4, 5.0)</td>
<td>3.1 ** (1.2, 5.0)</td>
<td>1.6 * (0.2, 3.0)</td>
</tr>
<tr>
<td>T4 (follow-up)</td>
<td>5.3 *** (3.8, 6.8)</td>
<td>5.6 *** (3.0, 8.1)</td>
<td>2.0 * (0.4, 3.7)</td>
</tr>
<tr>
<td>Female</td>
<td>−1.7 (−3.5, 0.1)</td>
<td>−4.0 *** (−6.3, −1.8)</td>
<td>−0.1 (−2.1, 2.0)</td>
</tr>
<tr>
<td>Age</td>
<td>−0.1 (−0.4, 0.2)</td>
<td>0.6 ** (0.2, 1.0)</td>
<td>0.6 ** (0.2, 0.9)</td>
</tr>
<tr>
<td>1+ Conditions</td>
<td>−0.8 (−2.7, 1.1)</td>
<td>0.6 (−1.8, 3.0)</td>
<td>−1.5 (−3.7, 0.7)</td>
</tr>
<tr>
<td>Not White</td>
<td>1.5 (−0.7, 3.6)</td>
<td>1.5 (−1.6, 4.6)</td>
<td>−2.2 (−4.6, 0.2)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>−1.0 (−4.1, 2.1)</td>
<td>−3.1 (−6.9, 0.6)</td>
<td>−1.4 (−4.9, 2.1)</td>
</tr>
<tr>
<td>High school or less</td>
<td>−1.3 (−3.2, 0.7)</td>
<td>−0.8 (−3.4, 1.8)</td>
<td>−2.5 * (−4.7, −0.3)</td>
</tr>
<tr>
<td>Incident NS</td>
<td>7.4 *** (5.2, 9.7)</td>
<td>----</td>
<td>1.6 (−0.9, 4.2)</td>
</tr>
<tr>
<td>Sickle Cell</td>
<td>4.3 ** (1.7, 7.0)</td>
<td>0.4 (−2.6, 3.3)</td>
<td>−0.3 (−3.3, 2.7)</td>
</tr>
<tr>
<td>Model $R^2$</td>
<td>0.22</td>
<td>0.18</td>
<td>0.07</td>
</tr>
<tr>
<td>Observations</td>
<td>744</td>
<td>446</td>
<td>737</td>
</tr>
<tr>
<td>Log Likelihood</td>
<td>−2,632.5</td>
<td>−1,568.5</td>
<td>−2,671.4</td>
</tr>
<tr>
<td>AIC</td>
<td>5,292.9</td>
<td>3,162.9</td>
<td>5,370.8</td>
</tr>
<tr>
<td>BIC</td>
<td>5,357.5</td>
<td>3,216.2</td>
<td>5,435.2</td>
</tr>
</tbody>
</table>

Note:

* $p<0.05$;  
** $p<0.01$;  
*** $p<0.001$;  

AIC = Akaike information criteria; BIC = Bayesian Information Criteria.

The intercept can be interpreted as the mean function score at T2 (event) for the reference group who are non-Hispanic white, 8-year old boys with cancer, no other health condition and a mother with education more than high school. The domain of Upper Extremity was not assessed in children with nephrotic syndrome.